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Abstract 70 
Background: The genetic etiology of primary immunodeficiency disease (PID) carries prognostic 71 
information.  72 
Objective: We conducted a whole-genome sequencing study assessing a large proportion of the NIHR-73 
BioResource – Rare Disease cohort.   74 
Methods: In the predominantly European study population of principally sporadic unrelated PID cases 75 
(n=846), a novel Bayesian method identified NFKB1 as one most strongly associated with PID, and the 76 
association was explained by 16 novel heterozygous truncating, missense and gene deletion variants. 77 
This accounted for 4% of common variable immunodeficiency (CVID) cases (n=390) in the cohort. Amino-78 
acid substitutions predicted to be pathogenic were assessed by analysis of structural protein data. 79 
Immunophenotyping, immunoblotting and ex vivo stimulation of lymphocytes determined the functional 80 
effects of these variants. Detailed clinical and pedigree information was collected for genotype-81 
phenotype co-segregation analyses.  82 
Results: Both sporadic and familial cases demonstrated evidence of the non-infective complications of 83 
CVID, including massive lymphadenopathy (24%), unexplained splenomegaly (48%) and autoimmune 84 
disease (48%), features prior studies correlate with worse clinical prognosis. Although partial penetrance 85 
of clinical symptoms was noted in certain pedigrees, all carriers have a deficiency in B lymphocyte 86 
differentiation. Detailed assessment of B lymphocyte numbers, phenotype and function identifies the 87 
presence of a raised CD21low B cell population: combined with identification of the disease-causing 88 
variant, this distinguishes between healthy individuals, asymptomatic carriers and clinically affected 89 
cases. 90 
Conclusion: We show that heterozygous loss-of-function variants in NFKB1 are the most common known 91 
monogenic cause of CVID that results in a temporally progressive defect in the formation of 92 
immunoglobulin-producing B cells.    93 
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Key Messages: 94 
• Pathogenic variants in NFKB1 are currently the most common known monogenic cause of CVID. 95 
• There is a clear association with complications such as autoimmunity and malignancy, features 96 
associated with worse prognosis. 97 
• These patients can be stratified by NFKB1 protein level and the B cell phenotype. 98 
 99 
Capsule Summary: 100 
Whole genome sequencing revealed 16 novel pathogenic truncating, missense and gene deletion 101 
variants in NFKB1.  Most mutations were linked to reduced protein expression, perturbed 102 
immunophenotyping and ex vivo stimulation assays of patients and relatives. 103 
 104 
Keywords:  105 
B cells, Common Variable Immunodeficiency, NF-κB1  106 
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Abbreviations used: 107 
CADD:   Combined Annotation Dependent Depletion 108 
CVID:   Common variable immunodeficiency  109 
ExAC:   Exome Aggregation Consortium  110 
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IMDM:   Iscove’s Modified Dulbecco’s medium 112 
InDels:   Insertions/deletions 113 
iNKT cells:  Invariant Natural Killer T cells 114 
LOF:   Loss-of-function 115 
MAF:   Minor allele frequency 116 
PBMCs:   Peripheral blood mononuclear cells 117 
PID:    Primary immunodeficiency disease 118 
PML:   Progressive multifocal leukoencephalopathy 119 
RHD:   Rel homology domain 120 
SNVs:   Single nucleotide variants 121 
VEP:   Variant Effect Predictor  122 
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Introduction 123 
Common variable immunodeficiency (CVID [MIM 607594]), which occurs in approximately 1:25,000 124 
people1-3, is a clinically and genetically heterogeneous disorder characterized by susceptibility to 125 
sinopulmonary infections, hypogammaglobulinemia and poor vaccine responses. CVID is the most 126 
common primary immune deficiency requiring life-long clinical follow up and the clinical course is highly 127 
variable with substantial excess mortality. Affected individuals frequently present with recurrent 128 
respiratory infections as well as immune dysregulatory features. The antibody deficiency is often not as 129 
marked as the agammaglobulinemia seen in the genetically defined conditions leading to B lymphocyte 130 
aplasia4,5. Conversely, while patients with B lymphocyte aplasia have a favorable prognosis on adequate 131 
replacement immunoglobulin treatment, the response of CVID patients is highly variable.    132 
 133 
Past studies focused on familial cases with CVID and used techniques ranging from traditional linkage 134 
analysis to more recent exome sequencing to characterize the genetic etiology. This has revealed that 135 
monogenic gene dysfunction accounts for 10% of cases4,5. Several of the variants in these genes have 136 
been characterized as partially penetrant; it remains unclear whether genetic or environmental factors 137 
determine disease onset. Multiple recent studies identified variants in NFKB1 as a monogenic cause of 138 
CVID and reported on the clinical features of these cases6-11. 139 
 140 
As part of this NIHR-BioResource – Rare Diseases study, we sequenced the genomes of 846 unrelated 141 
individuals with predominantly sporadic primary immunodeficiency (PID) who were recruited from 142 
across the UK and by European collaborators. Application of a recently developed statistical method 143 
BeviMed12 to the 846 PID cases and over 5,000 control genomes, identified NFKB1 as the gene with the 144 
highest probability of association with the disease, and with the largest number of cases explained by 145 
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variants in that gene. Further investigations revealed a series of 16 heterozygous loss-of-function (LOF) 146 
variants in NFKB1 as the most common genetic cause of CVID.  147 
 148 
Mutations in genes that affect NF-κB-dependent signaling are associated with a number of 149 
immunodeficiencies13-26. NF-κB is a ubiquitous transcription factor member of the Rel proto-oncogene 150 
family. NF-κB regulates the expression of several genes involved in inflammatory and immune responses. 151 
The classical activated form of NF-κB consists of a heterodimer of the p50/p65 protein subunits. The NF-152 
κB family of transcription factors comprises five related proteins, c-Rel, p65 (RelA), RelB, p50 (NF-κB1) 153 
and p52 (NF-κB2) that interact to form homodimers and heterodimers with distinct gene regulatory 154 
functions13,27-29. Each Rel NF-κB protein has a conserved 300-amino-acid N-terminal Rel homology 155 
domain (RHD) that encompasses sequences needed by NF-κB proteins to bind  DNA motifs (κB 156 
elements), to form dimers, to interact with regulatory inhibitor IκB proteins and to enter the nucleus. 157 
The ten different NF-κB dimers identified have distinct transcriptional properties28. In most cells, NF-κB 158 
is retained in the cytosol in a latent state through interaction with IκB proteins (such as IκBα, IκBβ and 159 
IκBε), a family of proteins with ankyrin repeats, that mediate IκB interaction with the RHD of NF-κB, 160 
masking the nuclear localization sequence and DNA-binding domains. Signal-dependent activation of an 161 
IκB kinase (IKK) complex comprising catalytic (α and β) and regulatory (NEMO) subunits, induces the 162 
phosphorylation and degradation of IκB29, which permits NF-κB factors to enter the nucleus and regulate 163 
gene expression. 164 
 165 
We show that variants in NFKB1 culminate in a progressive humoral immunodeficiency indistinguishable 166 
from CVID, with a highly variable penetrance. We demonstrate the utility of an in silico protein 167 
prediction model for validating the predicted disease-causing substitutions, and we report on the clinical 168 
spectrum, immunological phenotype and functional consequences of heterozygous NFKB1 variants.  169 
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Methods 170 
Cohort 171 
NIHR-BioResource – Rare Disease (NIHRBR-RD) study was established in the UK to further the clinical 172 
management of patients with rare diseases, by providing a national resource of whole genome sequence 173 
data. All participants provided written informed consent and the study was approved by the East of 174 
England Cambridge South national institutional review board (13/EE/0325). At the time of our analysis, 175 
the NIHRBR-RD study included whole genome sequence data from 8,066 individuals, of which 1,299 176 
were part of the PID cohort. These were predominantly singleton cases, but additional affected and/or 177 
unaffected family members of some of the patients were also sequenced; in total there were 846 178 
unrelated index cases.  179 
The PID patients were recruited by specialists in clinical immunology (either trained in pediatrics or 180 
internal medicine) from 26 hospitals in the UK, and a smaller number came from the Netherlands, France 181 
and Italy. The recruitment criteria included: clinical diagnosis of CVID according to the ESID criteria (ESID 182 
Registry – Working Definitions for Clinical Diagnosis of PID, 2014, latest version: April, 25, 2017); extreme 183 
autoimmunity; or recurrent (and/or unusual) infections suggestive of severely defective innate or cell-184 
mediated immunity. Exclusion of known causes of PID was encouraged, and some of the patients were 185 
screened for one or more PID genes prior to enrollment into the PID cohort. The ethnic make-up of the 186 
study cohort represented that of the general UK population: 82% were European, 6% Asian, 2% African, 187 
and 10% of mixed ethnicity, based on the patients’ whole genome data.  188 
Given that PID is a heterogeneous disease, with overlap in phenotypes and genetic etiologies across 189 
different diagnostic categories, we decided to perform an unbiased genetic analysis of all of 846 190 
unrelated index cases. Whole genome sequence data was additionally available for 63 affected and 345 191 
unaffected relatives. Within a broad range of phenotypes, CVID is the most common disease category, 192 
comprising 46% of the NIHRBR-RD PID cohort (n=390 index cases, range 0-93 years of age).  193 
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 194 
Sequencing and variant filtering 195 
Whole genome sequencing of paired-end reads was performed by Illumina on their HiSeq X Ten system. 196 
Reads of 100, 125 or 150 base pairs in length were aligned to the GRCh37 genome build using Isaac 197 
aligner, variants across the samples were jointly called with AGG tool, and large deletions were identified 198 
using Canvas and Manta algorithms (all software by Illumina), as described previously30. Average read 199 
depth was 35, with 95% of the genome covered by at least 20 reads. 200 
Single nucleotide variants (SNVs) and small insertions/deletions (InDels) were filtered based on the 201 
following criteria: passing standard Illumina quality filters in >80% of the genomes sequenced by the 202 
NIHRBR-RD study; having a Variant Effect Predictor (VEP)31 impact of either MODERATE or HIGH and 203 
having a minor allele frequency (MAF) <0.001 in the Exome Aggregation Consortium (ExAC) dataset, and 204 
MAF <0.01 in the NIHRBR-RD cohort. Large deletions called by both Canvas and Manta algorithms, 205 
passing standard Illumina quality filters, overlapping at least one exon, absent from control datasets32, 206 
and having frequency of <0.01 in the NIRBR-RD genomes were included in the analysis. 207 
All variants reported as disease-causing in this study were confirmed by Sanger sequencing using 208 
standard protocols. Large deletions were inspected in IGV plot (Figure E1) and breakpoints were 209 
confirmed by sequencing the PCR products spanning each deletion. 210 
 211 
Gene and variant pathogenicity estimation 212 
In order to evaluate genes for their association with PID, we applied the BeviMed inference procedure12 213 
to the NIHRBR-RD whole genome dataset. BeviMed (https://CRAN.R-project.org/package=BeviMed) 214 
evaluates the evidence for association between case/control status of unrelated individuals and allele 215 
counts at rare variant sites in a given locus. The method infers the posterior probabilities of association 216 
under dominant and recessive inheritance and, conditional on such an association, the posterior 217 
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probability of pathogenicity of each considered variant in the locus. BeviMed was applied to rare variants 218 
and large rare deletions in each gene, treating the 846 unrelated PID index cases as ‘cases’ and 5,097 219 
unrelated individuals from the rest of the NIHRBR-RD cohort as ‘controls’. All genes were assigned the 220 
same prior probability of association with the disease of 0.01, regardless of their previously published 221 
associations with an immune deficiency phenotype. Variants which had a VEP impact labelled HIGH were 222 
assigned higher prior probabilities of pathogenicity than variants with a MODERATE impact, as described 223 
previously12. 224 
 225 
Immunophenotyping and B and T cell functional assays 226 
Peripheral blood mononuclear cells (PBMCs) were isolated using standard density gradient 227 
centrifugation techniques using Lymphoprep (Nycomed, Oslo, Norway). Absolute numbers of 228 
lymphocytes, T cells, B cells and NK cells were determined with Multitest six-color reagents (BD 229 
Biosciences, San Jose, USA), according to manufacturer’s instructions. For the immunophenotyping of 230 
the PBMCs we refer to the Supplemental Methods of the Online Repository.  231 
 232 
To analyze the ex vivo activation of T and B cells, PBMCs were resuspended in PBS at a concentration of 233 
5–10×106 cells/ml and labeled with 0.5μM CFSE (Molecular Probes) as described previously33 and in the 234 
Supplemental Methods of the Online Repository. Proliferation of B and T cells was assessed by 235 
measuring CFSE dilution in combination with the same mAbs used for immunophenotyping. Analysis of 236 
cells was performed using a FACSCanto-II flowcytometer and FlowJo software. Patient samples were 237 
analyzed simultaneously with PBMCs from healthy controls. 238 
 239 
ELISA 240 
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The secretion of immunoglobulins by mature B cells was assessed by testing supernatants for secreted 241 
IgM, IgG and IgA with an in-house ELISA using polyclonal rabbit anti-human IgM, IgG and IgA reagents 242 
and a serum protein calibrator all from Dako (Glostrup, Denmark), as described previously33. 243 
 244 
SDS PAGE and Western Blot analysis 245 
Blood was separated into neutrophils and PBMCs. Neutrophils (5×106) were used for protein lysates, 246 
separated by SDS polyacrylamide gel electrophoresis and transferred onto a nitrocellulose membrane. 247 
Individual proteins were detected with antibodies against NF-κB p50 (mouse monoclonal antibody E-10, 248 
Santa Cruz Biotechnology, Texas, USA), against IκBα (rabbit polyclonal antiserum C-21, Santa Cruz 249 
Biotechnology) and against human glyceraldehyde-3-phosphate dehydrogenase, GAPDH (mouse 250 
monoclonal antibody, Merck Millipore, Darmstadt, Germany).  251 
Secondary antibodies were either goat anti-mouse-IgG IRDye 800CW, goat anti-rabbit-IgG IRDye 680CW 252 
or goat anti-mouse-IgG IRDye 680LT (LI-COR Biosciences, Lincoln, NE, USA). Relative fluorescence 253 
quantification of bound secondary antibodies was performed on an Odyssey Infrared Imaging system (LI-254 
COR Biosciences, Nebraska, USA), and normalized to GAPDH. 255 
 256 
NF-κB1 protein structure 257 
To gain structural information on the NF-κB1 RHD, a previously resolved crystal structure of the p50 258 
homodimer (A43-K353) bound to DNA was used34. Ankyrin repeats of NF-κB1 (Q498-D802) were 259 
modelled employing comparative homology modelling (Modeller 9v16) using the Ankyrin repeats crystal 260 
structure of NF-κB2 as template35,36. There is no structural information on the region between the 6th 261 
and 7th Ankyrin repeat (F751-V771)36 and was therefore omitted in the model. The death domain (G807-262 
S894) structure has been resolved by Saito and co-workers using NMR (pdb: 2bdf). 263 
 264 
Tuijnenburg et al 12 
 
Statistical analysis of lymphocyte data 265 
Differences between groups with one variable were calculated with a non-paired Student’s t-test or one-266 
way ANOVA with Bonferroni post-hoc test, differences between groups with two or more variables were 267 
calculated with two-way ANOVA with Bonferroni post-hoc test using GraphPad Prism 6. A P-value less 268 
than 0.05 was considered significant.  269 
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Results 270 
Pathogenic variants in NFKB1 are the most common monogenic cause of CVID 271 
In an unbiased approach to analysis, we obtained BeviMed posterior probabilities of association with PID 272 
for every individual gene in all 848 unrelated PID patients in the NIHR-BioResource – Rare Disease 273 
(NIHRBR-RD) study. Genes with posterior probabilities greater than 0.05 are shown in Figure 1, showing 274 
that NFKB1 has the strongest prediction of association with disease status (1.000). All 13 HIGH impact 275 
variants (large deletion, nonsense, frameshift and splice site) in NFKB1 were observed in cases only, 276 
resulting in the very high posterior probabilities of pathogenicity (mean 0.99) for this class of variants 277 
(Figure 2). On the other hand, MODERATE impact variants (missense substitutions) were observed both 278 
in cases and controls. The majority had near zero probability of pathogenicity, but three substitutions 279 
were observed in the PID cases only, and had posterior probabilities greater than 0.15 (Figure 2), 280 
suggesting their potential involvement in the disease. Genomic variants with a high Combined 281 
Annotation Dependent Depletion (CADD) score were found within both the PID and control cohorts, 282 
suggesting that this commonly used metric of variant deleteriousness cannot reliably distinguish disease-283 
causing from benign variants in NFKB1. All 16 predicted likely pathogenic variants were private to the PID 284 
cohort, and further investigation revealed that all 16 individuals were within the diagnostic criteria of 285 
CVID (Table 1).  286 
 287 
Assessment of all 390 CVID cases in our cohort for pathogenic variants showed that the next most 288 
commonly implicated genes are NKFB2 and BTK, with three explained cases each (Figure E2). 289 
Importantly, based on the gnomAD dataset of 135,000 predominantly healthy individuals, none of the 290 
NFKB1 variants reported here are observed in a single gnomAD individual, even though 90% of our CVID 291 
cohort, and all of the NFKB1-positive cases, had European ancestry. Therefore, our results suggest that 292 
LOF variants in NFKB1 are the most commonly identified monogenic cause of CVID in the European 293 
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population, with 16 out of 390 CVID cases explaining up to 4.1% of our cohort. None of the variants 294 
identified here had been reported in the previously described NFKB1 cases6-11. 295 
 296 
The NFKB1 gene encodes the p105 protein that is processed to produce the active DNA-binding p50 297 
subunit13. The 16 potentially pathogenic variants we identified were all located in the N-terminal p50 298 
part of the protein (Figure 2). The effects of the three rare substitutions on NF-κB1 structure were less 299 
clear than those of the truncating and gene deletion variants, so we assessed their position in the crystal 300 
structure of the p50 protein. Their location in the inner core of the RHD (Figure 3A) suggested a potential 301 
impact on protein stability, whereas other rare substitutions in the NIHRBR-RD cohort were found in 302 
locations less likely to affect this (Figure 2 and 3A, Figure E3).  303 
 304 
NF-κB1 LOF as the disease mechanism 305 
Twelve patients with truncating variants (Arg284*, His513Glnfs*28, c.160-1G>A and Asp451*), one 306 
patient with gene deletion (del 103370996-103528207) and three patients with putative protein 307 
destabilizing missense variants (Ile281Met, Val98Asp and Ile87Ser) were investigated for evidence of 308 
reduced protein level. Assessment of the NF-κB1 protein level in PBMCs or neutrophils in 9 index cases 309 
and 7 NFKB1 variant carrying relatives demonstrated a reduction in all individuals (Figure 3B, Figure E4). 310 
Relative fluorescence quantification of the bands confirmed this and demonstrated a protein level of 38 311 
± 4.3% (mean ± SEM) compared to healthy controls. There was no difference between clinically affected 312 
and clinically unaffected individuals (36 ± 4.4% versus 42 ± 10.1%, n=11 versus n=5, P=0.50). Our 313 
observations indicate that the pathogenic NFKB1 variants result in LOF of the NF-κB1 p50 subunit, as 314 
reduction in protein levels was seen in all carriers regardless of their clinical phenotype, and was absent 315 
in family members that were non-carriers.  316 
 317 
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Variable disease manifestations in NFKB1 LOF individuals 318 
Seven individuals had evidence of familial disease (Table 1), prompting us to investigate genotype-319 
phenotype co-segregation and disease penetrance in cases for which pedigree information and 320 
additional family members were available (Figure 4, Tables E1-3). The age at which 321 
hypogammaglobulinemia becomes clinically overt is highly variable (Figure E5), as illustrated by pedigree 322 
C in which the grandchildren carrying the c.160-1G>A splice-site variant had IgG subclass deficiency (C:III-323 
3 and C-III-4), in one case combined with an IgA deficiency (C:III-3). Although not yet overtly 324 
immunodeficient, the clinical course of their fathers (C:II-3 and C:II-5) and grandmother (C:I-2) predicts 325 
this potential outcome, and warrants long-term clinical follow up of these children.  326 
 327 
We also observed variants in individuals who were clinically asymptomatic. Pedigree A highlights variable 328 
disease penetrance: the healthy mother (A:II-1) carries the same Arg284* variant as two of her clinically 329 
affected children (A:III-2 and A:III-3). The identification of this nonsense variant prompted clinical 330 
assessment of the extended kindred and demonstrated that her sister (A:II-4) suffered from recurrent 331 
sinopulmonary disease and nasal polyps with serum hypogammaglobulinemia consistent with a CVID 332 
diagnosis. Overall, based on the clinical symptoms observed at the time of this study across six 333 
pedigrees, the penetrance of NFKB1 variants with respect to the clinical manifestation of CVID is 334 
incomplete (about 60% in our cohort, 11 affected individuals among 18 variant carriers), with varied 335 
expressivity not only of age at disease onset, but of specific disease manifestations even within the same 336 
pedigree. 337 
 338 
The clinical disease observed among the NFKB1 variant carriers is characteristic of progressive antibody 339 
deficiency associated with recurrent sinopulmonary infections (100% of clinically affected individuals), 340 
with encapsulated microbes such as Streptococcus pneumoniae and Haemophilus influenzae species 341 
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(Table E1). The clinical spectrum of NFKB1 LOF includes massive lymphadenopathy (24%), unexplained 342 
splenomegaly (48%) and autoimmune disease (48%) – either organ-specific and/or hematological of 343 
nature (mainly autoimmune hemolytic anemia and idiopathic thrombocytopenic purpura, Tables E1 and 344 
E2). The percentage of autoimmune complications is based on the presence of autoimmune cytopenias 345 
(autoimmune hemolytic anemia, idiopathic thrombocytopenic purpura (<50-75x106/mL), autoimmune 346 
neutropenia, Evans syndrome), alopecia areata/totalis, vitiligo and Hashimoto thyroiditis among the 347 
clinically affected cases. Granulomatous-lymphocytic interstitial lung disease and splenomegaly were 348 
considered lymphoproliferation. Enteropathy, liver disease, colitis and a mild decrease in platelet count 349 
(>100x106/mL) were neither included in those calculations nor scored separately. Histological 350 
assessment of liver disease found in three patients showed no evidence of autoimmune or 351 
granulomatous liver disease, though fibrosis and cirrhosis was observed, in these male patients. Finally, 352 
the number of oncological manifestations, predominantly hematological, was noticeable. There were 353 
two cases with solid tumors (parathyroid adenoma, breast cancer) and four cases with hematological 354 
malignancies (B-cell non-Hodgkin lymphoma, diffuse large B-cell lymphoma, follicular lymphoma, 355 
peripheral T-cell lymphoma), which add up to 6/21 cases, 28.6%. 356 
 357 
B cell phenotype in NFKB1 LOF individuals and immune cell activation 358 
Index cases and family members carrying NFKB1 variants were approached for repeat venipuncture for 359 
further functional assessment. In clinically affected individuals the B cell numbers and phenotype were 360 
indistinguishable from that described for CVID37 (Figure 5, Figure E6). However, in clinically unaffected 361 
individuals, the absolute B cell count was often normal or raised (Figure 5A). In all individuals with NFKB1 362 
LOF variants the numbers of switched memory B cells were reduced (Figure 5B-5D), while a broad range 363 
of non-switched memory B cells was observed. This demonstrates that while the clinical phenotype of 364 
NFKB1 LOF variants is partially penetrant, all carriers have a deficiency in class-switched memory B cell 365 
generation. The presence of raised numbers of the CD21low population described in CVID discriminates 366 
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between clinically affected and unaffected individuals with NFKB1 LOF variants (Figure 5E). The B cells 367 
from individuals with NFKB1 LOF variants demonstrated impaired proliferative responses to anti-368 
IgM/anti-CD40/IL-21 and CpG/IL-2 (Figure 6A); this corresponded with the inability to generate 369 
plasmablasts (CD38+/CD27++), most pronounced in the more extreme phenotypes, i.e. clinically affected 370 
cases (Figure 6B, Figure E7B). Similarly, ex vivo IgG production was reduced in individuals with LOF 371 
variants, whereas the level of IgM in the supernatants was normal (Figure 6C and 6D, Figure E7C), 372 
compatible with hypogammaglobulinemia.  373 
 374 
T cell phenotype in NFKB1 LOF individuals 375 
The T cell phenotype was largely normal in the subset distribution (Figure E8 and E9).  Similar to the 376 
knockout mouse model38, we found an aberrant number of invariant Natural Killer T (iNKT) cells in the 377 
clinically affected individuals (Figure E8). T cell proliferation was intact upon anti-CD3/anti-CD28 or IL-15 378 
activation (Figure E10). Since iNKT cells have been implicated in diverse immune reactions39, this 379 
deficiency may contribute to the residual disease burden in replacement immunoglobulin treated 380 
patients, some of whom had acute or chronic relapsing infection with herpes virus and, in one case, JC-381 
virus.382 
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Discussion 383 
In our study we show that LOF variants in NFKB1 are present in 4% of our cohort of CVID cases, being the 384 
most commonly identified genetic cause of CVID. Furthermore, we highlight specific features of these 385 
patients that distinguish them within the diagnostic category of "CVID", which otherwise applies to an 386 
indiscrete phenotype, acquired over time, that is termed ‘common’ and ‘variable’. The majority of the 387 
genetic variants we report here truncate or delete one copy of the gene; together with pedigree co-388 
segregation analyses, protein expression and the B cell functional data, we conclude that NFKB1 LOF 389 
variants are causing autosomal dominant haploinsufficiency. This has now been recognized as the 390 
genetic mode of inheritance for at least 17 known PIDs, including that associated with previously 391 
reported variants in NFKB16,40-42. In monogenic causes of PID, incomplete penetrance has been more 392 
frequently described in haploinsufficient, relative to dominant-negative, PID disease, having been 393 
reported in more than half of the monogenic autosomal dominant haploinsufficient immunological 394 
conditions described40. This may be because dominant-negative gain-of-function mutations cause 395 
disease by expression of an abnormal protein at any level while, as seen in this study, haploinsufficiency 396 
is predicted to lead to 50% residual function of the gene product. Incomplete penetrance of a genetic 397 
illness by definition will be associated with substantial variation in the clinical spectrum of disease, and 398 
the spectrum seen in this study is consistent with prior reports; in three pedigrees with 20 individuals6, 399 
harboring heterozygous mutant NFKB1 alleles, the age of onset varied from 2-64 years, with a high 400 
variety of disease severity, including two mutation carriers that were completely healthy at the age of 2 401 
and 43 years.  402 
 403 
It is important to temper skepticism of partial penetrance of immune genetic lesions with our knowledge 404 
that individual immune genes may have evolved in response to selection pressure for host protection 405 
against specific pathogens43. Consequently, within the relatively pathogen-free environment of 406 
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developed countries, the relevant pathogen for triggering disease may be scarce and reports 407 
documenting partial penetrance of the clinical phenotype will increase. This makes the traditional 408 
approaches of genetics for determining causality difficult. The BeviMed algorithm used in this study 409 
prioritized both the gene NFKB1 and individual variants within NFKB1 for contribution to causality; the 410 
power of methods like this will increase with greater data availability. The identification of a number of 411 
rare NFKB1 variants with high CADD scores both in PID and control datasets highlights the potential for 412 
false attribution of disease causality when the genetics of an individual case is considered outside the 413 
context of relevant control data.  414 
 415 
Currently healthy family members carrying the same NFKB1 LOF variant demonstrated similar reductions 416 
in p50 expression and low numbers of switched memory B cells as their relatives suffering from CVID. 417 
The longitudinal research investigation of these individuals could help identify the additional modifiers, 418 
including epigenetic or environmental factors, which influence the clinical penetrance of these genetic 419 
lesions. The similarity of results seen in patients with large heterozygous gene deletions and in those 420 
with more discrete substitutions is consistent with haploinsufficiency as the shared disease mechanism.  421 
 422 
In patients with mild antibody deficiency it is often difficult to decide when to initiate replacement 423 
immunoglobulin therapy; this may be the case for individuals and their family members identified with 424 
LOF NFKB1 variants. Two measures seem to correlate well with clinical disease: first, the class-switch 425 
defect and lower IgG and IgA production ex vivo. Immunoglobulin class-switching is known to be 426 
regulated by NF-κB. Mutations in the NF-κB essential modulator (NEMO) cause a class-switch defective 427 
hyper-IgM syndrome in humans20 as well as in the p50 knockout mice13,44,45. Haploinsufficiency of NF-κB 428 
may result in defective class-switch recombination due to poor expression of activation-induced cytidine 429 
deaminase (AID), a gene regulated by NF-κB, that, when absent, is also associated with 430 
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immunodeficiency46. Secondly, the ability to measure the CD21low  B cell population is widespread in 431 
diagnostic immunology laboratories and our study identifies this marker to correlate with NF-κB-disease 432 
activity. Although the function of these cells remain to be fully elucidated47, this laboratory test may be 433 
useful for the longitudinal assessment of clinically unaffected individuals identified with LOF NFKB1 434 
variants.   435 
 436 
Apart from suffering from recurrent and severe infections (including viral disease) for which these 437 
patients had been diagnosed with PID in the first place, autoimmunity and unexplained splenomegaly 438 
are very common manifestations in our patient cohort, similar to the other heterozygous NFKB1 cases 439 
described6-11. Although autoimmunity has been subject to variable percentages per cohort study3,48,49, it 440 
seems that these complications occur more frequently in NFKB1-haploinsufficient patients compared to 441 
unselected CVID cohorts. In contrast to IKAROS defects, but similar to CTLA4 haploinsufficiency, we 442 
observed that NFKB1-haploinsufficiency may also result in chronic and severe viral disease, as noted for 443 
CMV and JC virus infections in three of our patients. In the study of Maffucci et al.11, one of the NFKB1-444 
affected cases also suffered from Pneumocystis jirovecii and progressive multifocal leukoencephalopathy 445 
(PML), which is suggestive for JC virus infection. Whether the B cell defect in NFKB1-haploinsufficiency is 446 
responsible for these non-bacterial infections is unclear50,51. PML is most often discovered in the context 447 
of an immune reconstitution inflammatory syndrome, as seen in HIV patients on antiretroviral therapy, 448 
and in multiple sclerosis patients after natalizumab discontinuation52. Although the exact contribution of 449 
B cell depletion in PML pathogenesis is unknown, the increased PML risk in rituximab-treated patients53 450 
suggests a protective role for B cells. 451 
 452 
Three individuals in this cohort suffered from liver failure and an additional three of transaminitis. 453 
Although autoimmunity is suspected, a non-hematopoietic origin of liver disease cannot be excluded in 454 
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the absence of autoantibodies and nodular regenerative disease. Mouse models have suggested a non-455 
immune role for NF-κB signaling in liver failure13,54-56.  456 
 457 
In the cohort of NFKB1 patients we identified a number of malignancies. Malignancies in PID patients 458 
have been cited as the second-leading cause of death after infection57,58, and murine-models have 459 
demonstrated that haploinsufficiency of NF-κB1 is a risk factor for hematological malignancy59. In a large 460 
CVID registry study on 2,212 patients, 9% had malignancies, with one-third being lymphomas, some 461 
presenting prior to their CVID diagnosis49. Despite the fact that our cohort is relatively small, we found 462 
oncological manifestations in 29% of our cases (two-third being lymphoma), suggesting that 463 
malignancies in NFKB1-haploinsufficiency may occur more often than in unselected CVID patients. In a 464 
study in 176 CVID patients, among the 626 relatives of patients with CVID, no increase in cancer risk was 465 
observed60, suggesting that when this does occur, as in this study (three out of seven), it may be due to a 466 
shared genetic lesion. Therefore, in a pedigree with a LOF variant in NFKB1, any relatives with cancer 467 
should be suspected of sharing the same pathogenic variant.  468 
 469 
In conclusion, previous publications61,62 have suggested that CVID is largely a polygenic disease. Our 470 
results provide further evidence that LOF variants in NFKB1 are the most common monogenic cause of 471 
disease to date, even in seemingly sporadic cases. In these patients there is a clear association with 472 
complications such as malignancy, autoimmunity and severe non-immune liver disease; this is important 473 
since the excess mortality seen in CVID occurs in this group48. The screening for defined pathogenic 474 
NFKB1 variants accompanied by B cell phenotype assessment, has prognostic management and is 475 
effective in stratifying these patients.   476 
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Table 1. Summary of the CVID patients’ clinical presentation and their NFKB1 variants. 678 
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A Familial ●   103504037 C>T nonsense c.850C>T;Arg284* 
B Familial ● ● ○ 103518717 delCATGC frameshift c.1539_1543del;His513Glnfs*28 
C Familial ● ● ●○ 103459014 G>A splice-acceptor c.160-1G>A;? 
D Familial ● ●  103518801 delGA nonsense c.1621_1622del; Asp541* 
E Sporadic ● ● ○ 103504030 C>G missense c.843C>G;Ile281Met 
F Sporadic ●  ● 103488178 T>A missense c.293T>A;Val98Asp 
G Sporadic ●   103488145 T>G missense c.260T>G;Ile87Ser 
H Familial ● ●  103501798 T>C splice-donor c.835+2T>C;? 
I Sporadic ●   103370996-103528207 - large deletion - 
J Familial ●   103517415 delG frameshift c.1423del;Ala475Profs*10 
K Sporadic ● ● ● 103436974-103652655 - large deletion - 
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P Sporadic ● ●  103505914 delG frameshift c.1005del;Arg336Glyfs*96 
Closed dots, presence of symptoms in index patient   679 
Open dots, presence of symptoms in family member of index patient 680 
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Figure 1. Overall BeviMed results showing that NFKB1 has the highest posterior probability of 682 
association with disease in the NIHRBR-RD PID cohort. Genes with variants previously reported to cause 683 
PID are highlighted in red. Genes with posterior probabilities > 0.05 are shown. 684 
 685 
Figure 2. Plot of rare missense, truncating and gene deletion NFKB1 variants identified in the NIHRBR-686 
RD genomes of unrelated individuals, and their location relative to NFKB1 domains. The tracks from 687 
left to right show: number of unrelated case (red) and control (black) individuals in whom each variant 688 
was observed; the four major NFKB1 domains; gray bars representing each exon in transcript 689 
ENST00000226574; variant annotation relative to transcript ENST00000226574 and genomic location of 690 
large deletions, with VEP HIGH impact variants and large deletions highlighted in blue; CADD scores of all 691 
nonsense, frameshift, splice and missense variants; ExAC allele frequencies; conditional probability of 692 
variant pathogenicity inferred using BeviMed. Only variants labelled as MODERATE or HIGH impact 693 
relative to the canonical transcript ENST00000226574 are shown. The initial inference that formed part 694 
of the genome-wide analysis included variant chr4:103423325G>A, which was observed in one control 695 
sample. This variant is intronic (LOW impact) relative to ENST00000226574 but is a splice variant (HIGH 696 
impact) relative to the minor transcript ENST00000505458. As variants were filtered based on the 697 
highest impact variant annotation against any Ensembl transcript, this variant was originally included in 698 
the inference. For this plot, the inference was re-run including only missense, truncating and gene 699 
deletion variants relative to the canonical transcript. 700 
  701 
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Figure 3. NFKB1 LOF variants lead to haploinsufficiency of the p50 protein. (A) Localization of RHD 702 
substitutions with a high CADD score (>20) within the structure of the NF-κB p50 monomer. Shown is a 703 
solid (top panel) and a transparent (bottom panel) sphere representation of the NF-κB p50 monomer. 704 
Perturbed residues indicated in green were observed in a control dataset and are located on the outside 705 
of the structure, while the residues shown in red were perturbed exclusively in the PID cohort and are 706 
buried inside the structure. (B) Western blot analysis targeting p50, IκBα and GAPDH of NFKB1 variant 707 
carriers. Left, representative blot of a healthy control and patient B-II:1; Right, summary of 16 NFKB1 708 
variant carriers showing haploinsufficiency, expressed as percentage of healthy controls on the same 709 
blot corrected for GAPDH, mean ± SEM. 710 
 711 
Figure 4. Pedigrees of familial NFKB1 cases. Six affected families for which pedigree information and 712 
additional family members were available. Proband/index cases indicated with P. 713 
 714 
Figure 5. Decreased class-switched memory B cells and increased CD21low B cells in NFKB1 LOF variant 715 
carriers. (A) Absolute numbers of CD19+ B cells; each dot represents a single individual and their age. In 716 
grey are age-dependent reference values. (B-E) Percentages within CD19+CD20+ B lymphocytes of (B) 717 
CD27+IgD+ (non-switched memory or marginal-zone B cells) and CD27+IgD- (switched memory B cells), or 718 
(C) CD27+IgG+, or (D) CD27+IgA+, or (E) CD21lowCD38low/dim. (HD healthy donor; CU clinically unaffected or 719 
CA clinically affected individuals with LOF variant in NFKB1.) Gating strategy is shown in Figure E6A. Only 720 
individuals with sufficient B cells could be analyzed. P-values were determined by one-way (Figure 5E) or 721 
two-way (Figure 5B) ANOVA with Bonferroni post-hoc test or unpaired Student’s t-test (Figure 5C,D), ns 722 
not significant, **P≤0.01, ***P≤0.001.  723 
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Figure 6. The ex vivo class switch recombination defect of individuals carrying NFKB1 LOF variants is 724 
linked to the more extreme phenotype. 6 day culture of CFSE-labeled lymphocytes normalized for B cell 725 
number unstimulated, CpG/IL-2 (T cell independent activation) or anti-IgM/anti-CD40/IL-21 (T cell 726 
dependent activation). (A) Percentage of divided B cells as measured by CFSE dilution (B) Percentage of 727 
CD27++ plasmablasts. Gating strategy is shown in Figure E7A. (C, D) IgM and IgG production in 728 
supernatant of 6 day culture. (HD healthy donor; CU clinically unaffected or CA clinically affected 729 
individuals with LOF variant in NFKB1.) Only individuals with sufficient B cells could be analyzed. P-values 730 
were determined by two-way ANOVA with Bonferroni post-hoc test, ns not significant, **P≤0.01, 731 
***P≤0.001. 732 
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Supplemental Figure Legends 
Figure E1. IGV plot of large NFKB1 deletion. IGV plot of patient I:II-1 showing the large NFKB1 deletion 
identified by 50% reduction in the number of reads from the whole genome sequencing data mapping to 
that region. 
 
Figure E2. Numbers of CVID patients per gene in which we identified a likely pathogenic variant fully 
explaining the patient’s phenotype. Assessment of all 390 CVID cases in our cohort identified 31 
patients with a monogenic defect in 11 different genes. Variants in NFKB1 contributed to more than half 
of all CVID patients with a monogenic diagnosis (16/31, 52%). NKFB2 and BTK were the next most 
commonly implicated genes, with three explained cases each.  
 
Figure E3. Protein model of high-impact missense variants in and proximal to the ANK domain. 
Residues observed with missense variants containing a high CADD score (≥20) are highlighted. Most of 
these are situated on the protein exterior (green) and appear equally in the primary immunodeficiency 
cohort and non-primary immunodeficiency cohorts (Figure 2). A623G (#19) appears to be located more 
interior, although mutation of an Alanine to Glycine is a moderate substitution. Equally notable are 
residues of the Ankyrin repeats which previously have been probed as interaction sites upon NF-κB 
dimerization. While R614 (#7), K684 (#8), L517 (#13) and R687 (#16) could be considered part of these 
putative interaction sites, variants at these sites are found in non-primary immunodeficiency patients 
(Figure 2). 
 
Figure E4. Western blot analysis of all tested NFKB1 variant carriers. Western blot analysis targeting 
p50, IκBα and GAPDH of NFKB1 variant carriers. Twelve patients with truncating variants (Arg284*, 
His513Glnfs*28, c.160-1G>A and Asp451*), one patient with gene deletion (del 103370996-103528207) 
and three patients with putative protein destabilizing missense variants (Ile281Met, Val98Asp and 
Ile87Ser) were tested. Relative fluorescence quantification of p50 and GAPDH by Odyssey Infrared 
Imaging system above and below each western blot. IκBα was not targeted in the Case D western blot. 
 
Figure E5. Serum IgM, IgG and IgA levels in serum of NFKB1 LOF variant carrier. Each dot represents an 
NFKB1 LOF variant carrier and their age. In grey age-dependent reference values.  
 
Figure E6. Gating strategy for Figure 5B-E and additional B cell analyses. (A) Representative flow 
cytometry plots of a healthy control, patient A:II-1 (clinically unaffected) and patient A:II-4 (clinically 
affected). Phenotype of CD19+CD20+ B lymphocytes. Numbers represent percentages in corresponding 
quadrants. (B) Percentages of CD27−IgD+ (naïve) or CD27−IgD+CD24+CD38+ (transitional) B cells. (HD 
healthy donor, NFKB1+/- individual with NFKB1 LOF variant.) Only individuals with sufficient B cells could 
be analyzed. P-values were determined by two-way ANOVA with Bonferroni post-hoc test (naïve B cells) 
or Student’s t-test (transitional B cells), ns not significant, **P≤0.01. 
 
Figure E7. Gating strategy Figure 6A and 6B and formation of CD38+ plasmablasts and IgA production. 
(A) Representative flow cytometry plots of a healthy control and patient A:II-4 (clinically affected) after a 
6 day culture of CFSE-labeled lymphocytes normalized for B cell number unstimulated, CpG/IL-2 (T cell 
independent activation) and anti-IgM/anti-CD40/IL-21 (T cell dependent activation). B cells gated on 
CD19+CD20−/+ and subsequently on CD27++ (left) and CFSE and CD38 (right). Numbers represent 
percentages in corresponding quadrants. (B) Plasmablast formation measured by proliferation and CD38 
upregulation (CFSE−CD38+). (C) IgA production in the supernatant. (HD healthy donor; CU clinically 
unaffected or CA clinically affected individuals with LOF variant in NFKB1.) Only individuals with sufficient 
B cells could be analyzed. P-values were determined by two-way ANOVA with Bonferroni post-hoc test, 
ns not significant, **P≤0.01, ***P≤0.001. 
 
Figure E8. Additional lymphocyte numbers in individuals with NFKB1 LOF variants. Absolute numbers 
of total lymphocytes (CD45+), CD4+ and CD8+ T cells, NK cells (CD3−CD16+CD56+) and invariant natural 
killer T cells (CD3+Vα24+Vβ11+). Each dot represents a single individual and their age. In grey age-
dependent normal values.  
 
Figure E9. Normal T cell differentiation in individuals with NF-κB1 deficiency. (A) Representative flow 
cytometry dot plots of a healthy control and patient E:II-1, defining the differentiation of CD3+CD4+ and 
CD3+CD8+ T lymphocytes with CD27 and CD45RA. (B, C) Summary of subsets of (B) CD4+ T cells and (C) 
CD8+ T cells. (HD healthy donor, NFKB1+/- individual with NFKB1 LOF variant.) P-values were determined 
by two-way ANOVA with Bonferroni post-hoc test, ns not significant. 
 
Figure E10. T cells of individuals with NFKB1 variants (NFKB1+/-) show normal proliferative capacity. 6 
day culture of CFSE-labeled lymphocytes unstimulated, anti-CD3/anti-CD28 (T cell receptor stimulation) 
or IL-15. Percentage of CD4+ or CD8+ T cell specific cell division as measured by CFSE dilution. (HD healthy 
donor, NFKB1+/- individual with NFKB1 LOF variant.) P-values were determined by two-way ANOVA with 
Bonferroni post-hoc test, ns not significant.  
[0 - 56]
Patient I:II-1
NFKB1 MANBA
BTK
3 CD19
1
CD40LG
1
DOCK8
1
ICOS
1
LRBA
1
NFKB1
16
NFKB2
3
PIK3R1
2
RAG2
1
STAT1
1
131
5 6 7 8
10
122
9
11
15 16 17 18
43
14 19
1. D519N 11. A742T
2. V532I 12. C704F
3. R534H 13. L517V
4. P793R 14. R734M
5. N500K 15. D697N
6. V539L 16. R687H
7. R614G 17. S662N
8. K684N 18. A624T
9. R850W 19. A623G
10. V865I
12.4 6.0
32.0 32.6
p50
IκBα
GAPDH
16.9
30.4 28.0
5.2 6.6
26.1 27.7
5.5
30.3
6.0 2.8
49 52
p50
IκBα
GAPDH
1.4
30
0.6
31
1.52 1.67
76.8 66.2
p50
IκBα
GAPDH
3.59
57.7
3.20 2.12
200 213
p50
IκBα
GAPDH
0.94 0.77
296 270
0.73 0.77
268 282
0.67 0.36
40.7 47.6
p50
GAPDH
0.70
53.1
5.3
H
D
H
D
C
:I-2
C
:III-1
C
:III-4
C
:III-3
D
:II-2
D
:I-2
B
:II-1
E:II-1
A:II-1
A:II-4
A
:III-2
Case ACase B Case C
Case D
Case E
I:II-1
Case I
J:III-2
Case J
c.160-1G>A Ile281Met Arg284*
Ala475Profs*10
His513Glnfs*28
Asp541*Large deletion
H
D HD
H
D
H
D
H
D
A
:III-3
Case F
Val98Asp
Case G
Ile87Ser
F:II-1
G
:II-1
Clinically affected Clinically unaffected Clinically affected (post IVIG)
0 10
0
5
10
15
20
20 30 40 50 60 70 80
Immunoglobulin G
Age (years)
Im
m
un
og
lo
bu
lin
G
(g
/L
)
0 10
0
1
2
3
4
5
20 30 40 50 60 70 80
Immunoglobulin  A
Age (years)
Im
m
un
og
lo
bu
lin
A
(g
/L
)
0 10
0.0
0.5
1.0
1.5
2.0
2.5
20 30 40 50 60 70 80
Immunoglobulin M
Age (years)
Im
m
un
og
lo
bu
lin
M
(g
/L
)
ACD27 CD27
Ig
G
CD27
Ig
A
CD38
CD
21
Control
Ig
D
48 49
21
58 15
198
1 2
4849
4 11
2461
0 0
5148
1 5
3164
24
7
12
0 0
1684
1 0
1682
81 16
21
A:II-1
A:II-4
B
HD NFKB1+/-
Transitional B cells
%
HD NFKB1+/-
Naive B cells
%
Clinically unaected
Clinically aected
0
5
10
15
20
25 ns
0
25
50
75
100
**
C:I-2
C:III-1
C:III-4
C:III-3
D:II-2
D:I-2B:II-1 E:II-1A:II-1
A:II-4
A:III-2
Case A Case B Case C Case D Case E
I:II-1
Case I
J:III-2
Case J
c.160-1G>A Ile281MetArg284* Ala475Profs*10His513Glnfs*28 Asp541* Large deletion
ACD27 CFSE CFSECD27
Unstimulated CpG/IL-2
Control
Ig
D
CD
38
Ig
D
CD
38
CFSECD27
Ig
D
CD
38
αIgM/αCD40/IL-21
0
0
0
0
6
6 0
31
1
0 0
31
1
0 0
0 38
37 1
54 18
18 0
71
A:II-4
HD CU CA HD CU CA HD CU CA
0
10
20
30
40
50
60
70
CFSE-CD38+
%
NFKB1+/-
Unstimulated CpG/IL-2 αIgM/αCD40/IL-21
NFKB1+/-NFKB1+/-
** **
ns
ns
ns
ns
HD CU CA HD CU CA
0
100
200
300
400
500
2000
4000
6000
IgA production
ng
/m
l
Unstimulated CpG/IL-2
NFKB1+/-NFKB1+/-
***
ns **
B C
C:I-2
C:III-1
C:III-4
C:III-3
D:II-2
D:I-2B:II-1 E:II-1A:II-1
A:II-4
A:III-2
Case A Case B Case C Case D Case E
c.160-1G>A Ile281MetArg284* His513Glnfs*28 Asp541*
Clinically affected Clinically unaffected
0 10
0
2000
4000
6000
20 30 40 50 60 70 80
Lymphocytes
Age (years)
C
D
45
+
Ly
m
ph
oc
yt
es
(n
o.
/m
m
3 )
0 10
0
500
1000
1500
2000
2500
20 30 40 50 60 70 80
CD4+ T cells
Age (years)
C
D
4+
T
ce
lls
(n
o.
/m
m
3 )
0 10
0
500
1000
1500
20 30 40 50 60 70 80
CD8+ T cells
Age (years)
C
D
8+
T
ce
lls
(n
o.
/m
m
3 )
0 10
0
500
1000
1500
20 30 40 50 60 70 80
NK cells
Age (years)
C
D
16
+ C
D
56
+
N
K
ce
lls
(n
o.
/m
m
3 )
0 10
0.0
0.1
0.2
0.3
0.4
0.5
20 30 40 50 60 70 80
1
3
5
iNKT cells
Age (years)
C
D
3+
TC
R
V α
24
+ V
β
11
+
iN
K
T
ce
lls
(n
o.
/m
m
3 )
BC
A
Control
CD27 CD27
CD
45
RA
CD
45
RA
16 28
550 60
364
17 26
570 70
282
CD4+ CD8+
E:II-1
C:I-2
C:III-1
C:III-4
C:III-3
D:II-2
D:I-2
B:II-1
E:II-1
A:II-1
A:II-4
A:III-2
F:II-1
G:II-1
A:III-3
I:II-1
J:III-2
HD NFKB1+/- HD NFKB1+/- HD NFKB1+/- HD NFKB1+/-
0
20
40
60
80
100
CD4+ T cell subsets
%
Naive Memory Effector Memory Highly differentiated
ns ns ns ns
HD NFKB1+/- HD NFKB1+/- HD NFKB1+/-
0
20
40
60
80
100
CD8+ T cell subsets
%
Naive Memory Effector Memory
ns ns ns
Case A
Case B
Case C
Case D
Case E
Case I
Case J
c.160-1G>A
Ile281Met
Arg284*
Ala475Profs*10
His513Glnfs*28
Asp541*
Large deletion
Case F
Val98Asp
Case G
Ile87Ser
HD NFKB1+/- HD NFKB1+/- HD NFKB1+/-
0
20
40
60
80
100
Divided CD4 + T cells
%
Unstimulated αCD3/αCD28 IL-15
ns
ns
HD NFKB1+/- HD NFKB1+/- HD NFKB1+/-
0
20
40
60
80
100
Divided CD8 + T cells
%
Unstimulated αCD3/αCD28 IL-15
ns
ns
C:I-2
C:III-4
C:III-3
D:II-2
D:I-2
A:II-1
A:II-4
A:III-2
F:II-1
A:III-3
Case A
Case C
Case D
c.160-1G>A
Arg284*
Asp541*
Case F
Val98Asp
Table E1. Clinical data of individuals carrying NFKB1 variants    
 
Case ID 
Year 
of 
birth  
Age at 
PID 
diagnosis 
Clinical 
diagnosis 
 
Major symptoms at onset  Infections Autoimmunity / autoinflammation Malignancy  Survival 
Case A 
A:II-1 1961 - Healthy - - - - - 
A:II-4 1963 2015 CVID Sinusitis 2012 Pneumonia 2015 S. pneumoniae - - - 
A:III-2 1989 1992 XLA - 
Frequent 
sinopulmonary 
infections 
- - - 
A:III-3 1995 2005 XLA Pneumonias 2002 
EBV-related 
splenomegaly 2005 
JC-virus 2016 
- (splenomegaly) - - 
Case B 
B:I-1 1939 1967 CVID 
Appendicitis-abscess 1965 
Bacterial meningitis 1967  
Pneumonias 1967 
S. pneumoniae AIHA 2005 
B-NHL (EBV-negative) 
2007  
 
Died 2007:  
heart attack 
B:II-1 1968 2011 CVID Pneumonias  2010 S. pneumoniae,  H. influenzae 
Alopecia areata 1988 
Vitiligo 1989 
Hypothyroiditis 2003 
- - 
Case C 
C:I-2 1938 1990 CVID 
Sinusitis 
Pneumonias 
ICU respiratory failure (1978) 
Bronchiectasis 
S. pneumoniae,  
H. influenzae 
Sister and her children 
have autoimmune 
disease (MS, IDDM1 & 
SLE)  
Parathyroid adenoma - 
C:II-3 1972 1988 CVID Pneumonias Bronchiectasis   IDDM1  
Died in 2008:  
during 2nd OLT 
(1st OLT 2005) 
C:II-5 1972 1985 CVID 
OMAs  
Oral ulcers 
Sore throats 
H. influenzae  
S. pneumoniae 
C. albicans 
A. fumigatus 
- DLBCL (EBV-neg) 
Died in 2011: 
DLBCL  
 
C:III-1 1999 - Healthy - - - - - 
C:III-3 2001 - Healthy - - - - - 
C:III-4 2004 - Healthy - - - - - 
Case D 
D:I-2 1958 - Healthy - - Thyroid disease - - 
D:II-2 1981 1999 CVID ITP and anemia Hypogammaglobulinemia 
Pneumonias 
Sinusitis 
ITP 
Splenomegaly - - 
Asthma E. coli, urinary tract 
infections 
GLILD 
Periodontitis 
Case E 
E:II-1 1992 1999 ALPS 
Bronchiectasis 
Hypogammaglobulinemia 
following multiple courses of 
Rituximab therapy 
Chest infections 
Sinusitis 
Autoimmune 
neutropenia 
ITP 
- - 
Case F 
F:II-1 1946 2000 CVID 
Severe pneumonias 
Bronchiectasis  
Lung fibrosis                                                                                     
Cellulitis R leg 
-                                           Hyperthyroidism 
Follicular lymphoma 
(2005); recurrence 
(2008) 
- 
Case G 
G:II-1 1980 2001 CVID Severe pneumonia Bronchiectasis 
COPD lobectomy (2009) 
M. avium  
Mild splenomegaly                                                                                     
Chronic diarrhea - - 
Case H 
H:II-1 1973 1997 CVID ITP and AIHA Splenomegaly 
Pneumonia 
Sinusitis 
Invasive CMV 
Chronic diarrhea with 
villous atrophy - 
Died in 2008 
CMV 
Case I 
I:II-1 1991 2009 CVID 
Multi-dermatomal shingles (age 
12) 
Recurrent pneumonia 
Bronchiectasis 
Sinusitis 
S. pneumoniae 
H. influenzae 
 
Mild thrombocytopenia - - 
Case J 
J:III-2 1969 2004 CVID 
Recurrent pneumonia 
Sinusitis, otitis media 
Recurrent prostatitis 
M. catarrhalis 
H. influenzae 
P. aeruginosa 
S. pneumoniae 
2011 CMV DNA 
detected in urine 
Diabetes 
(corticosteroid-
induced) 
- - 
Case K 
K:II-1 1952 1996 CVID 
Recurrent pneumonias, otitis 
and sinusitis 
Pneumococcal meningitis 
P. aeruginosa 
H. influenzae 
S. pneumonia 
S. marcescens 
AIHA 
Peripheral T-cell 
lymphoma, received 
CHOP 
- 
Case L 
L:II-1 1969 1991 CVID 
Initially few symptoms – tested 
for IgG levels when her brother 
died of bacterial meningitis on 
 AIHA 1999 (splenectomy) - - 
background recurrent 
respiratory infections and low 
Ig’s. Respiratory infections soon 
became apparent. 
Case M 
M:II-1 1985 2012 CVID 
Respiratory infections, with 
bronchiectasis and chronic 
sinusitis. 
Chronic diarrhea 
P. aeruginosa 
(bronchi/sinuses- 
2012,3,4,5,6),  
S. aureus 2015,6, RSV 
2015, atypical myco-
bacterium infection 
2009, C. difficile - year 
unknown, plantar warts 
(HPV), ongoing Herpes 
Zoster, disseminated 
2011 (while on 
azathioprine) 
Evans syndrome 2009 
(Rituximab) 
Autoimmune 
enteropathy 2010 
Vitamin B12 deficiency 
(suspected pernicious 
anemia) 
 
- - 
Case N 
N:II-1 1959 2015 CVID 
Hypogammaglobulinemia.  
Generalised lymphadenopathy 
and  splenomegaly 
Pancytopenia 
EBV, CMV  
Neutropenic sepsis 
(without positive 
cultures) 
Alopecia totalis Breast cancer  
Case O 
O:II-1 1978 2001 CVID Frequent bacterial infections Chronic diarrhea  Giardia lamblia - - - 
Case P 
P:II-1 1961 2004 CVID 
AIHA (treated with Rituximab 
2012). 
ITP and autoimmune 
neutropenia. 
Recurrent sinus and respiratory 
tract infections  
Chronic Norovirus 
Rhinovirus 
H. influenzae 
S. pneumoniae 
GLILD. 
 
Polyarthritis (RA-like: 
RF/ANA negative) 
- - 
 
Note: 
H. influenzae strains are non-typeable (= uncapsulated) unless mentioned specifically. 
Abbreviations: 
AIHA: Autoimmune haemolytic anaemia; B-NHL: B non-Hodgkin lymphoma; CVID: Common variable immunodeficiency; DLBCL: Diffuse Large B cell lymphoma; 
GLILD: Granulomatous-lymphocytic inflammatory lung disease; ITP: immune thrombocytopenia; OLT: Orthopic liver transplantation; XLA: X-linked 
agammaglobulinemia    
Table E2. Symptoms and organ involvement in individuals carrying NFKB1 variants    
Case ID Year of birth  Lung Lymph nodes Spleen Liver function 
Gastro-intestinal 
tract Brain 
Case A 
A:II-1 1961 - - - - - - 
A:II-4 1963 - - - - - - 
A:III-2 1989 - - - - - - 
A:III-3 1995 - Enlarged 
Splenectomy for 
splenomegaly, 
suspected malignancy 
Transaminitis  - - 
Case B 
B:I-1 1939 - - Splenomegaly Hepatomegaly - - 
B:II-1 1968 - - - - - - 
Case C 
C:I-2 1938 Bronchiectasis  Lung fibrosis - - Transaminitis  - - 
C:II-3 1972 Bronchiectasis  Enlarged (cervical and axillary) Enlarged 
Liver fibrosis (1998) 
without granulomas, 
no signs of infection or 
autoimmunity 
- - 
C:II-5 1972 Bronchiectasis - - 
Liver cirrhosis (1996), 
suspect of hepatitis C 
virus infection 
Duodenal partial villous 
blunting, no granuloma 
and absence of colonic 
plasmacells 
Tremor 
C:III-1 1999 - - - - - - 
C:III-3 2001 - - - - - - 
C:III-4 2004 - - - - - - 
Case D 
D:I-2 1958 - - - - - - 
D:II-2 1981 GLILD - Splenomegaly Normal - - 
Case E 
E:II-1 1992 Bronchiectasis Enlarged as a child; biopsies unremarkable 
Splenomegaly 
(previous ITP) Normal - - 
Case F 
F:II-1 1946 Bronchiectasis, fibrosis - - - - - 
Case G 
G:II-1 1980 Bronchiectasis, fibrosis - - - - - 
Case H 
H:II-1 1973 - - Splenomegaly - Chronic diarrhea with villous atrophy CMV retinitis 
Case I 
I:II-1 1991 Bronchiectasis Enlarged (mediastinal) Splenomegaly 
Mild elevation 
transaminases, 
gamma-GT 
- - 
Case J 
J:III-2 1969 Bronchiectasis (2005) Asthma - - Normal 
Intermittent diarrhoea 
and abdominal pain - 
Case K 
K:II-1 1952 Bronchiectasis (2009) 
Previous peripheral T 
cell lymphoma: 
CD3+CD8+ (2015) 
 
Splenomegaly 
(previous AIHA) - - - 
Case L 
L:II-1 1969 
Chronic left lower lobe 
collapse, COPD 
(smoker), no 
bronchiectasis 
- Splenectomy (AIHA) Normal - - 
Case M 
M:II-1 1985 
Bronchiectasis.  
No interstitial disease.  
Nodule top left lung 
- 'Mild' splenomegaly on CT only Normal 
Autoimmune 
enteropathy (2011) - 
Case N 
N:II-1 1959 NAD Generalised Lymphadenopathy Large splenomegaly Normal - - 
Case O 
O:II-1 1978 NAD - - Normal - - 
Case P 
P:II-1 1961 GLILD bronchiectasis - 
Splenomegaly (2012), 
normalized over time  
 
 
Nodular regenerative 
hyperplasia of the liver.  
Chronic diarrhea: upon 
biopsies absence of 
plasmacells (Norovirus-
positive).  
 
- 
 
Abbreviations: 
AIHA: Autoimmune haemolytic anaemia; GLILD: Granulomatous-lymphocytic inflammatory lung disease; ITP: immune thrombocytopenia; NAD: No active 
disease 
Table E3. Immunological findings in individuals carrying NFKB1 variants                                
Case ID 
 
Year of 
birth 
Absolute 
lymphocyte 
count 
Abs # 
CD3+ T 
cells 
Abs # 
CD3/CD4+ 
T cells 
Abs # 
CD3/CD8+ 
T cells 
Abs # 
CD16/56+ 
NK cells 
Abs # 
CD19+ B 
cells 
IgA level 
(g/L) 
IgG level 
(g/L) - 
prior to Ig 
subst. 
IgM level 
(g/L) 
ANA, 
other 
autoAbs 
Case A 
A:II-1 1961 1.427 0.978 (68.5%) 
0.624 
(43.7%) 
0.332 
(23.3%) 
0.228 
(16.0%) 
0.215 
(15.0%) 0.13 1.5 0.44 ANA neg 
A:II-4 1963 3.288 1.974 (60.0%) 
1.305 
(39.7%) 
0.630 
(19.2%) 
0.981 
(29.9%) 
0.323 
(9.8%) 0.03 
12.1 
(post IVIG) 0.44 ANA neg 
A:III-2 1989 1.630 1.400 (85.9%) 
0.403 
(24.7%) 
0.941 
(57.8%) 
0.153 
(9.4%) 
0.074 
(4.5%) <0.04 6.9 0.17 ANA neg 
A:III-3 1995 2.527 2.269 (89.8%) 
0.735 
(29.1%) 
1.401 
(55.5%) 
0.252 
(10.0%) 0 (<0.50%) <0.04 6.2 <0.03 ANA neg 
Case B 
B:I-1 1939 1.189 0.820 (69,0%) 
0.240 
(20.0%) 
0.540 
(44.0%) 
0.060 
(5.0%) 
0.290 
(25.0%) <0.1 <0.05 0.26 Coomb’s pos 
B:II-1 1968 1.936 1.551 (80.1%) 
1.257 
(64.9%) 
0.284 
(14.7%) 
0.077 
(4.0%) 
0.291 
(15.01%) 0.1 1.7 0.36 Anti-TPO pos 
Case C 
C:I-2 1938 1.741 1.316 (75.6%) 
0.243 
(14.0%) 
0.943 
(54.2%) 
0.375 
(21.5%) 
0.047 
(2.7%) <0.1 2.0 0.6 - 
C:II-3 1972 0.950 0.870 (91.6%) 
0.450 
(47.4%) 
0.410 
(43.2%) 
0.060 
(6.3%) 
0.020 
(2.1%) <0.1 1.5 0.20 IDDM1 
C:II-5 1972 1.150 0.980 (85.2%) 
0.650 
(56.5%) 
0.331 
(28.8%) 
0.100 
(8.7%) 
0.042 
(3.7%) <0.1 1.4 0.20 - 
C:III-1 1999 2.959 2.027 (68.5%) 
1.038 
(35.1%) 
0.867 
(29.3%) 
0.306 
(10.3%) 
0.597 
(20.2%) 0.8 10.4 0.7 - 
C:III-3 2001 3.458 1.919 (55.5%) 
1.156 
(33.4%) 
0.591 
(17.1%) 
0.687 
(19.9%) 
0.749 
(21.7%) 0.6 
6.4 
(low IgG2) 0.2 - 
C:III-4 2004 4.054 2.615 (64.5%) 
1.565 
(38.6%) 
0.821 
(20.3%) 
0.514 
(12.7%) 
0.883 
(21.8%) 1.3 
5.7 
(low IgG2 
and IgG3) 
0.7 - 
Case D 
D:I-2 1958 2.5 1.373 (54.9%) 
0.761 
(30.4%) 
0.553 
(22.1%) NA 
0.173 
(6.9%) 2.3 11.0 0.84 - 
D:II-2 1981 1.200 0.679 (55.6%) 
0.504 
(42.0%) 
0.140 
(11.7%) NA 
0.027 
(2.2%) <0.3 4.9 <0.1 - 
Case E 
E:II-1 1992 1.046 0.963 (92.1%) 
0.709 
(67.8%) 
0.203 
(19.4%) NA 
0.022 
(2.1%) <0.1 3.9 <0.1 - 
Case F 
F:II-1 1946 0.619 0.458 (74.0%) 
0.174 
(28.1%) 
0.283 
(45.7%) NA 0 <0.1 <2 <0.1 - 
Case G 
G:II-1 1980 1.022 0.684 (66.9%) 
0.449 
(43.9%) 
0.235 
(23.0%) NA 0 <0.1 <3.9 <0.1 - 
Case H 
H:II-1 1973 5.458 (splenectomy) 
4.857 
(89%) 
2.129 
(39%) 
2.620 
(48%) 
0.262 
(4.8%) 
0.132 
(3%) 0.02 0.1 0.03 
Coomb’s pos 
ANA pos 
Case I 
I:II-1 1991 1.4 1.102 (78%) 
0.717 
(51%) 
0.349 
(25%) 
0.166 
(12%) 
0.122 
(7%) <0.06 0.3 0.09 - 
Case J 
J:III-2 1969 1.7 1.336 (78.6%) 
0.706 
(41.5%) 
0.602 
(35.4%) 
0.019 
(1.1%) 
0.318 
(18.7%) <0.07 <1.0 0.17 - 
Case K 
K:II-1 1952 0.7 0.639 (97%) 
0.206 
(31%) 
0.388 
(59%) 
0.005 
(1%) 
0.015 
(2%) 0.05 <0.1 <0.1 Coomb’s pos 
Case L 
L:II-1 1969 1.4 1.129 (77%) 
0.687 
(47%) 
0.405 
(28%) 
0.249 
(17%) 
0.080 
(5%) <0.05 
10.3 
(post SCIG) <0.05 Coomb’s pos 
Case M 
M:II-1 1985 1.0 0.902 (90%) 
0.621 
(62%) 
0.223 
(22%) 
0.055 
(5.5%) 
0.028 
(2.8%) <0.04 
Low pre Ig 
replacement 0.65 
Coomb’s pos, 
ANA neg 
Case N 
N:II-1 1959 1.012 0.82 (81%) 
0.54 
(53%) 
0.26 
(28%) 
0.15 
(16%) 
0.02 
(2%) <0.07 2.3 0.18 ANA neg 
Case O 
O:II-1 1978 1.7 1.39 (82%) 
0.97 
(57%) 
0.40 
(24%) 
0.06 
(3.5%) 
0.24 
(14%) 0.4 4.6 0.3 ANA neg 
Case P 
P:II-1 1961 0.79 0.52 (66%) 
0.33 
(42%) 
0.18 
(23%) 
0.11 
(14%) 
0.15 
(19%) <0.1 1.9 0.1 
Coomb’s pos 
ANA neg 
 
Abbreviations: 
NA: Not Available 
Supplemental Methods 
Immunophenotyping 
Peripheral blood mononuclear cells (PBMCs) were isolated using standard density gradient 
centrifugation techniques using Lymphoprep (Nycomed, Oslo, Norway). Absolute numbers of 
lymphocytes, T cells, B cells and NK cells were determined with Multitest six-color reagents (BD 
Biosciences, San Jose, USA), according to manufacturer’s instructions. For the immunophenotyping the 
PBMCs were resuspended in PBS, containing 0.5% (w/v) BSA and 0.01% sodium azide and incubated with 
saturating concentrations of fluorescently labeled conjugated monoclonal antibodies. Analysis of cells 
was performed using a FACSCanto-II flowcytometer and FlowJo software. Patient samples were analyzed 
simultaneously with PBMCs from healthy controls. The following directly conjugated monoclonal 
antibodies were used: CD4 PE-Cy7 [348809], CD8 PerCP-Cy5.5 [341050], CD20 PerCP-Cy5.5 [332781], 
CD21 FITC [561372], CD27 APC [337169], CD38 PE-Cy7 [335825], CD45 APC-Cy7 [348815], IgD PE 
[555779], and TCRγδ FITC [347903] from BD (San Jose, USA), CD3 Alexa 700 [56-0038-41], CD19 Alexa 
700 [56-0199-42] and CD27 APC-eFluor 780 [47-0279-42] from eBioscience (San Diego, USA), CD24 FITC 
[M1605] and CD27 FITC [M1764] from Sanquin (Amsterdam, the Netherlands), CD45RA (2H4-RD1) PE 
[6603181], TCRαβ PE [PN A39499], TCR Vα24 FITC [PM IM1589] and TCR Vβ11 PE [PN IM2290] from 
Beckman Coulter (Brea, USA), IgM FITC [F0317] and IgG FITC [F0158] from Dako (Glostrup, Denmark), IgA 
FITC [130-093-071] from Miltenyi Biotec (Bergisch Gladbach, Germany). 
 
B and T cell functional assay 
To analyze the ex vivo activation of T and B cells, PBMCs were resuspended in PBS at a concentration of 
5–10×106 cells/ml and labeled with 0.5μM CFSE (Molecular Probes) in PBS for 10 minutes at 37°C under 
constant agitation. Cells were washed and subsequently resuspended in Iscove’s Modified Dulbecco’s 
medium (IMDM) supplemented with 10% fetal calf serum (BioWhittaker), antibiotics, and 3.57×10–
4%(v/v) β-mercaptoethanol (Merck). Labeled PBMCs containing a fixed number of 2×104 (96-well plate) 
or 10×104 B cells (48-well plate) per well in a flat-bottom plate for 6 days at 37°C and stimulated with 
saturating amounts of anti-IgM mAb (clone MH15; Sanquin), anti-CD40 mAb (clone 14G7; Sanquin) and 
20ng/ml IL-21 (Invitrogen), or 1μg/ml CpG oligodeoxynucleotide 2006 (Invivogen) and 100U/ml IL-2 (R&D 
Systems), or anti-CD3 (clone 1xE) and anti-CD28 (clone 15E8), or IL-15 (R&D Systems). Proliferation of B 
and T cells was assessed by measuring CFSE dilution in combination with the same mAbs used for 
immunophenotyping and analyzed using a FACSCanto-II flowcytometer and FlowJo software. 
